

N. S. Garmash

Summary

The article presents the data of the efficacy of fluticasone propionate in treatment of moderate severity asthma with persistent course. The study was conducted in allergic center of Cherkassy Regional Hospital. 30 patients (19 males and 11 females) aged from 24 to 62 with a diagnosis of asthma of moderate severity with persistent course were admitted to this study. The group included non-smokers and patients who has no cardiovascular, endocrine, digestive system diseases and respiratory infections in the last 8 weeks. Patients received fluticasone propionate in dose 125 mcg twice a day via a new generation of cyclohaler – Fantasma during the study period. During the study that lasted 12 weeks, patients visited hospital four times where tests of asthma control and determining lung function were performed. According to study results 12-weeks treatment with fluticasone propionate in cyclohaler (125 mcg twice a day), positive changes in the subjective state of patients and in terms of respiratory function have been noted. The author concludes, that assignment of fluticasone propionate in cyclohaler (125 mcg twice a day) is an effective and safe treatment of bronchial asthma of moderate severity.

Key words: *bronchial asthma, fluticasone, new generation cyclohaler.*

Theoretical and practical J. «Asthma and Allergy», 2015, 2

N. S. Garmash

Chief of allergology center

SI «Cherkasy Regional Hospital of Cherkasy Regional Council»

18009, Ukraine, Cherkasy, str. Mendeleev, 3

tel.: +38(047)237-62-92